An insight into Project Optimus

In August 2024, the US Food and Drug Administration (FDA) released new guidance for the Project Optimus initiative, titled “Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases”. 9 months on, how has oncology drug development shifted? We have Meredith Manuel, Head of Business Development at Scendea in the hot seat to provide the insight.

For more information on Project Optimus or for help in intelligently navigating the guidance, get in touch...